American Gene Technologies

11:15 AM - 11:30 AM, Wednesday, October 23, 2019 ・ 2nd Floor
American Gene Technologies (AGT) is a gene and cell therapy company with a proprietary gene-delivery platform to rapidly develop gene and cell therapies to cure infectious diseases, cancers, and monogenic disorders. The Company’s mission is to transform people’s lives through genetic medicines that rid the body of disease. The Company expects to take its patented lead candidate for an HIV cure into the clinic in 2019. AGT has received five patents for its unique immuno-oncology approach to stimulate the human body’s natural immune system’s gamma-delta (γδ) T cells to destroy a variety of solid tumors. The Company has also developed a synthetic gene which it expects to cure Phenylketonuria (PKU), a debilitating rare disease. AGT’s treatment for PKU has been granted an Orphan Drug Designation by the Food and Drug Administration (FDA) and it is expected to reach the clinic in 2020.
Company Type:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
HIV cure (autologous T cell therapy - AGT103-T)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided